Name: Name:2-Methyl-1-phenyl-4-(pyridin-2-yl)-2-(2-(pyridin-2-yl)ethyl)butan-1-one
Brand: AABLOCKS
SKU: AA00ABIA
Rating: 90 (10 reviews)

Catalog No.: AA00ABIA

195371-52-9 | 2-Methyl-1-phenyl-4-(pyridin-2-yl)-2-(2-(pyridin-2-yl)ethyl)butan-1-one

Pack Size： 1mg

Purity： ≥95%

in stock

$46.00 $32.00

Pack Size： 5mg

Purity： ≥95%

in stock

$112.00 $78.00

Pack Size： 10mg

Purity： ≥95%

in stock

$175.00 $122.00

Pack Size： 25mg

Purity： ≥95%

in stock

$382.00 $267.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA00ABIA

Chemical Name: 2-Methyl-1-phenyl-4-(pyridin-2-yl)-2-(2-(pyridin-2-yl)ethyl)butan-1-one

CAS Number: 195371-52-9

Molecular Formula: C23H24N2O

Molecular Weight: 344.4495

MDL Number: MFCD00023550

SMILES: O=C(C(CCc1ccccn1)(CCc1ccccn1)C)c1ccccc1

NSC Number: 42834

Properties

Complexity: 408

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 26

Hydrogen Bond Acceptor Count: 3

Hydrogen Bond Donor Count: 0

Isotope Atom Count: 0

Rotatable Bond Count: 8

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 4.5

Literature fold

Title: Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.

Journal: Molecular cancer therapeutics20080801

Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology20060501

Title: Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7(8):2308-18.

Title: Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11(2): 117-124.

Title: Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5):663-670.